Appropriate advancement of type 2 diabetes therapy—CME Information

Continue to Article

CME Test
FREE 1.5 CME Credits

Release Date: October 1, 2007

Expiration Date: October 31, 2008

The purpose of this activity is to inform all clinicians who are interested in enhancing their diabetes management skills, including internists, primary care physicians, family practitioners, physician assistants, nurse practitioners, and other health care professionals. The focus is on optimizing management of type 2 diabetes.

Target Audience

This activity is designed for internists, primary care physicians, family practitioners, physician assistants, nurse practitioners, and other health care professionals.

Learning Objectives

Upon the completion of this activity, participants should be able to:

• Describe the appropriate treatment approach for patients newly diagnosed with type 2 diabetes

• Discuss the role of patient education in diabetes management

• Define the role of basal and prandial insulin in a comprehensive treatment strategy for type 2 diabetes

• Discuss the appropriate use of newer medications in the management of type 2 diabetes

Method of Instruction

Participants should read the learning objectives and review the activity in its entirety. After reviewing the material, complete the posttest consisting of a series of multiple-choice questions.

The activity is complemented with references that contain the rationale for the correct answer to each question as well as a description identifying the section of the activity that contains the correct answer, allowing participants to review the material as needed, thus finalizing their educational participation.

Upon completing this activity as designed and achieving a passing score of 70% or more on the posttest, participants will receive a letter of credit awarding 1.5 AMA/PRA Category 1 Credit(s)™ four (4) weeks after receipt of the posttest, registration, and evaluation materials.

Estimated time to complete this activity as designed is 1.5 hours.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of UMDNJ–Center for Continuing and Outreach Education and Embryon. UMDNJ–Center for Continuing and Outreach Education is accredited by the ACCME to provide continuing medical education for physicians.

UMDNJ–Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation.

Disclosures

• Luigi Meneghini, MD, has received research support from Merck & Co., Inc., Novo Nordisk Pharmaceutical, Inc., and sanofi-aventis, US, and is on the advisory panel for NiPRO Diabetes Systems. He is a consultant for Medtronic Mini Med, Inc., Novo Nordisk Pharmaceutical, Inc., and sanofi-aventis, US, and on the speakers bureau for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Medtronic Mini Med, Inc., Novo Nordisk Pharmaceutical, Inc., and sanofi-aventis, US.

• Laurence Kennedy, MD, is a consultant for MannKind Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc., and sanofi-aventis, US. He has received honoraria from Amylin Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., and sanofi-aventis, US, and is on the speakers bureau for Amylin Pharmaceuticals, Inc., Merck & Co., Inc., and sanofi-aventis, US.

• Ronald Koff, MD, has received honoraria from Abbott/KOS, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc., Eli Lilly and Company, Pri-Med, Reliant Pharmaceuticals, Inc., sanofi-aventis, US, and Takeda Pharmaceuticals North America, Inc.

• Louis Kuritzky, MD, has been on the speakers bureau or served as a consultant for Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., sanofi-aventis, US, and Takeda Pharmaceuticals North America, Inc.

• Sandra Leal, PharmD, CDE, has no financial relationships to disclose.

• Kevin Peterson, MD, MPH, has received honoraria from Pfizer Inc. and consultant fees from sanofi-aventis, US.

• Virginia Zamudio, RN, MSN, CDE, is a consultant and speaker for Pfizer Inc.

• Rameck R. Hunt, MD, Syed Naved Hasan, MD, and Kinshasa Morton, MD, have no financial relationships to disclose.

CME Academic Advisors

Faculty

Rameck R. Hunt, MD

University Medical Center at Princeton

Princeton Healthcare Medical Associates

Princeton, New Jersey

Field Testers

Syed Naved Hasan, MD, and Kinshasa Morton, MD

Off-Label Usage Disclosure

This activity contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. Product is not included in the labeling approved by the US Food and Drug Administration for the treatment of diabetes.

Jointly Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ)–Center for Continuing and Outreach Education and Embryon

This activity is supported by an educational grant from sanofi-aventis, US.

This material has been submitted by Embryon, Inc. It has been edited and peer reviewed by The Journal of Family Practice and Current Clinical Practice.

Continue to Article